NMRA

$0.00

(

0.00%

)
Quote details

stock

Neumora Therapeutics, Inc.

NASDAQ | NMRA

1.45

USD

$0.00

(

0.00%

)

At Close (As of Sep 17, 2025)

$242.92M

Market Cap

-

P/E Ratio

-1.57

EPS

$17.19

52 Week High

$0.61

52 Week Low

HEALTHCARE

Sector

NMRA Chart

Recent Chart
Price Action

NMRA Technicals

Tags:

NMRA Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$263M
Selling General And Administrative $63M
Research And Development $201M
Operating Expenses $263M
Investment Income Net -
Net Interest Income $20M
Interest Income $20M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $631K
Income Before Tax -$244M
Income Tax Expense $178K
Interest And Debt Expense -
Net Income From Continuing Operations -$244M
Comprehensive Income Net Of Tax -
Ebit -$244M
Ebitda -$243M
Net Income -$244M

Revenue & Profitability

Earnings Performance

NMRA Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $317M
Total Current Assets $314M
Cash And Cash Equivalents At Carrying Value $142M
Cash And Short Term Investments $142M
Inventory -
Current Net Receivables -
Total Non Current Assets $2.9M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments $0
Short Term Investments $165M
Other Current Assets $6.5M
Other Non Current Assets -
Total Liabilities $30M
Total Current Liabilities $30M
Current Accounts Payable $3.3M
Deferred Revenue -
Current Debt -
Short Term Debt $1.9M
Total Non Current Liabilities $22K
Capital Lease Obligations $1.9M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $1.9M
Other Current Liabilities $25M
Other Non Current Liabilities $22K
Total Shareholder Equity $287M
Treasury Stock -
Retained Earnings -$947M
Common Stock $16K
Common Stock Shares Outstanding $159M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$183M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $631K
Capital Expenditures $0
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$71M
Cashflow From Financing $22M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity $0
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$244M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$263M
Selling General And Administrative $63M
Research And Development $201M
Operating Expenses $263M
Investment Income Net -
Net Interest Income $20M
Interest Income $20M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $631K
Income Before Tax -$244M
Income Tax Expense $178K
Interest And Debt Expense -
Net Income From Continuing Operations -$244M
Comprehensive Income Net Of Tax -
Ebit -$244M
Ebitda -$243M
Net Income -$244M

NMRA News

NMRA Profile

Neumora Therapeutics, Inc. Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on pioneering therapies for brain diseases, including neuropsychiatric and neurodegenerative disorders. Based in Watertown, Massachusetts, Neumora is leveraging innovative science and technology to address significant unmet medical needs in the neurology space. The company aims to transform patient care by advancing its pipeline of novel compounds that target critical biological pathways associated with these complex diseases.

ATCH
+87.36%
$1.62
NVDA
-2.62%
$170.29
PLUG
+19.04%
$2.00
CGBS
-39.47%
$0.03
CDT
+40.10%
$0.89
BITF
+5.53%
$3.05
SNAP
+3.16%
$7.98
NFE
+8.00%
$2.16
SPRC
+142.93%
$4.47
NIO
+6.05%
$7.44
QBTS
+19.44%
$22.66
GRAB
-3.48%
$6.10
TSLA
+1.00%
$425.86
AAL
+0.84%
$12.51
LYFT
+13.12%
$22.84
GV
+68.16%
$2.80
NUAI
-4.00%
$0.45
MARA
-1.08%
$17.34
SOUN
+3.25%
$15.16
SOFI
-1.02%
$27.14
RGTI
+9.92%
$21.98
TPIC
-45.91%
$0.12
PLTR
-1.13%
$168.33
DNN
+1.40%
$2.53
AXDX
-61.36%
$0.03
ADAP
-1.22%
$0.08
BBD
+2.95%
$3.30
PGRE
-11.43%
$6.54
F
+0.52%
$11.67
INTC
-1.46%
$24.90
BMNR
+1.98%
$57.04
TNMG
-0.27%
$0.32
IPM
+22.79%
$2.37
LYT
-16.77%
$0.09
JOBY
-1.59%
$14.16
BTG
+0.46%
$4.34
MULN
-12.58%
$0.06
WBD
-1.42%
$17.98
RR
+2.84%
$3.98
NAKA
-4.66%
$1.43
KDLY
-4.66%
$1.43
RIVN
-1.46%
$14.11
AAPL
+0.35%
$238.99
PFE
+0.62%
$24.05
UBER
-4.95%
$92.98
ACHR
-1.20%
$9.00
ONDS
+0.16%
$6.10
QS
+1.08%
$10.26
IONQ
+4.97%
$65.36
ABEV
0.00%
$2.36
AIRE
-1.57%
$1.25
LDI
+2.70%
$4.55
RIOT
+0.82%
$17.66
RMBL
+60.50%
$3.21
WULF
+3.74%
$11.35
ADD
-25.47%
$0.05
RELI
+6.58%
$0.72
OPI
-31.80%
$0.56
TLRY
-2.45%
$1.19
AMD
-0.60%
$159.49
ETHD
-1.52%
$3.22
SRM
+53.27%
$10.30
VALE
-0.27%
$10.88
BINI
-10.60%
$0.05
HOOD
+1.07%
$118.64
DVLT
-22.98%
$0.34
NOK
+1.84%
$4.69
QUBT
+4.97%
$17.71
CIFR
+7.55%
$12.38
GOOGL
-0.64%
$249.53
IREN
+3.97%
$37.90
NWTN
+12.58%
$1.70
CWD
+19.05%
$7.56
AMZN
-1.40%
$230.76
ATYR
-5.09%
$1.02
JD
+1.52%
$35.24
ITUB
+1.82%
$7.27
INFY
+3.60%
$17.67
RZLV
-3.60%
$7.08
RIG
-1.87%
$3.40
FAAS
-6.04%
$0.09
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
KEY
+0.42%
$18.71
BABA
+2.39%
$166.09
BAC
+1.41%
$51.37
BTE
-2.49%
$2.54
WLGS
-5.57%
$0.04
BURU
-0.86%
$0.13
T
-0.97%
$29.33
HBAN
+0.63%
$17.54
CLSK
+2.14%
$11.44
JBLU
0.00%
$5.07
HIMS
-1.08%
$50.34
ETWO
0.00%
$3.30
CAN
+0.23%
$0.80
PEB
+2.03%
$11.79
RAYA
-3.83%
$0.04
GDXD
+2.45%
$1.25
IONZ
-10.28%
$4.80
ATCH
+87.36%
$1.62
NVDA
-2.62%
$170.29
PLUG
+19.04%
$2.00
CGBS
-39.47%
$0.03
CDT
+40.10%
$0.89
BITF
+5.53%
$3.05
SNAP
+3.16%
$7.98
NFE
+8.00%
$2.16
SPRC
+142.93%
$4.47
NIO
+6.05%
$7.44
QBTS
+19.44%
$22.66
GRAB
-3.48%
$6.10
TSLA
+1.00%
$425.86
AAL
+0.84%
$12.51
LYFT
+13.12%
$22.84
GV
+68.16%
$2.80
NUAI
-4.00%
$0.45
MARA
-1.08%
$17.34
SOUN
+3.25%
$15.16
SOFI
-1.02%
$27.14
RGTI
+9.92%
$21.98
TPIC
-45.91%
$0.12
PLTR
-1.13%
$168.33
DNN
+1.40%
$2.53
AXDX
-61.36%
$0.03
ADAP
-1.22%
$0.08
BBD
+2.95%
$3.30
PGRE
-11.43%
$6.54
F
+0.52%
$11.67
INTC
-1.46%
$24.90
BMNR
+1.98%
$57.04
TNMG
-0.27%
$0.32
IPM
+22.79%
$2.37
LYT
-16.77%
$0.09
JOBY
-1.59%
$14.16
BTG
+0.46%
$4.34
MULN
-12.58%
$0.06
WBD
-1.42%
$17.98
RR
+2.84%
$3.98
NAKA
-4.66%
$1.43
KDLY
-4.66%
$1.43
RIVN
-1.46%
$14.11
AAPL
+0.35%
$238.99
PFE
+0.62%
$24.05
UBER
-4.95%
$92.98
ACHR
-1.20%
$9.00
ONDS
+0.16%
$6.10
QS
+1.08%
$10.26
IONQ
+4.97%
$65.36
ABEV
0.00%
$2.36
AIRE
-1.57%
$1.25
LDI
+2.70%
$4.55
RIOT
+0.82%
$17.66
RMBL
+60.50%
$3.21
WULF
+3.74%
$11.35
ADD
-25.47%
$0.05
RELI
+6.58%
$0.72
OPI
-31.80%
$0.56
TLRY
-2.45%
$1.19
AMD
-0.60%
$159.49
ETHD
-1.52%
$3.22
SRM
+53.27%
$10.30
VALE
-0.27%
$10.88
BINI
-10.60%
$0.05
HOOD
+1.07%
$118.64
DVLT
-22.98%
$0.34
NOK
+1.84%
$4.69
QUBT
+4.97%
$17.71
CIFR
+7.55%
$12.38
GOOGL
-0.64%
$249.53
IREN
+3.97%
$37.90
NWTN
+12.58%
$1.70
CWD
+19.05%
$7.56
AMZN
-1.40%
$230.76
ATYR
-5.09%
$1.02
JD
+1.52%
$35.24
ITUB
+1.82%
$7.27
INFY
+3.60%
$17.67
RZLV
-3.60%
$7.08
RIG
-1.87%
$3.40
FAAS
-6.04%
$0.09
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
KEY
+0.42%
$18.71
BABA
+2.39%
$166.09
BAC
+1.41%
$51.37
BTE
-2.49%
$2.54
WLGS
-5.57%
$0.04
BURU
-0.86%
$0.13
T
-0.97%
$29.33
HBAN
+0.63%
$17.54
CLSK
+2.14%
$11.44
JBLU
0.00%
$5.07
HIMS
-1.08%
$50.34
ETWO
0.00%
$3.30
CAN
+0.23%
$0.80
PEB
+2.03%
$11.79
RAYA
-3.83%
$0.04
GDXD
+2.45%
$1.25
IONZ
-10.28%
$4.80

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.